Repatha®: What It Does, Who It’s For, and What the Evidence Shows

Repatha® is one of the more important additions to cardiovascular medicine in the past decade, but it is also a medication many patients know very little about.

Its generic name is evolocumab. It belongs to a class of medications known as PCSK9 inhibitors, and unlike statins, ezetimibe or bempedoic acid, it is given by injection rather than taken as a pill.

The interest in Repatha is understandable. It can produce a large reduction in LDL cholesterol, lower ApoB, modestly lower lipoprotein(a), and has randomized clinical trial evidence showing that it reduces cardiovascular events in appropriately selected patients. Coronary imaging studies have also demonstrated regression of atherosclerotic plaque and changes consistent with greater plaque stability.

That does not make Repatha a replacement for nutrition, exercise, metabolic health, blood pressure control, smoking avoidance or the rest of cardiovascular prevention. Nor does it mean every person with an elevated LDL cholesterol level should receive an injectable medication.

Its usefulness becomes clearer when the question is more specific: How much atherosclerotic cardiovascular risk does this person have, how much ApoB-containing particle reduction is needed, and what treatment can realistically get them there?

What Repatha Actually Does

PCSK9 is a protein involved in regulating LDL receptors on the surface of liver cells. Those receptors remove LDL particles from the bloodstream.

When PCSK9 binds to an LDL receptor, the receptor is more likely to be broken down rather than recycled back to the liver-cell surface. Evolocumab is a monoclonal antibody that binds PCSK9. With less PCSK9 available, more LDL receptors remain active and can continue clearing LDL particles from circulation.

The result is a degree of LDL reduction that is difficult to achieve with lifestyle intervention alone. Across clinical studies, evolocumab has generally reduced LDL cholesterol by approximately 50–60 percent, with some variation according to the underlying population and other therapies being used.

This is not simply a change in the amount of cholesterol carried inside LDL particles. Because most circulating LDL particles contain one ApoB molecule, reducing those particles also lowers ApoB. That distinction matters because ApoB reflects the number of atherogenic particles capable of entering the arterial wall and participating in atherosclerosis.

LDL Is Important, but ApoB Helps Explain Why This Matters

Traditional cholesterol discussions often focus almost entirely on LDL cholesterol. LDL-C remains clinically important, but it tells us how much cholesterol is being carried within LDL particles rather than directly counting the number of atherogenic particles.

ApoB provides another view. Each LDL particle, VLDL remnant, IDL particle and lipoprotein(a) particle carries one ApoB molecule. ApoB therefore serves as a practical estimate of the concentration of circulating particles capable of entering the arterial wall.

Repatha lowers both LDL-C and ApoB because it increases hepatic clearance of these particles. For someone with established atherosclerotic cardiovascular disease, familial hypercholesterolemia or substantial residual ApoB burden despite other treatment, that magnitude of reduction can be clinically useful.

This is also why we do not view cholesterol treatment at HormoneSynergy® as simply trying to make a laboratory number look better. The goal is to reduce exposure of the arterial wall to atherogenic particles in patients whose cardiovascular risk makes that reduction worthwhile.

Does Repatha Actually Reduce Heart Attacks?

Yes. This is an important distinction because lowering a biomarker is not enough to establish that a treatment improves clinical outcomes.

The FOURIER trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease who were already receiving statin therapy. Adding evolocumab lowered LDL substantially and reduced the trial's primary cardiovascular endpoint, which included cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina and coronary revascularization.

Over a median follow-up of approximately 2.2 years, the primary endpoint was reduced by about 15 percent relative to placebo. The narrower endpoint of cardiovascular death, myocardial infarction or stroke was also reduced. The trial did not demonstrate a significant mortality reduction during that relatively short follow-up period.

Those details matter. Repatha should not be described as eliminating cardiovascular risk, and an impressive LDL reduction should not be confused with complete protection from heart disease. Atherosclerosis develops through years of exposure to multiple risk factors, including ApoB-containing particles, smoking, hypertension, diabetes, insulin resistance, kidney disease and genetics.

What FOURIER demonstrated is more specific: in patients with established cardiovascular disease, substantial additional LDL lowering with evolocumab translated into fewer cardiovascular events.

What Happens to Existing Plaque?

Another common misconception is that lipid-lowering therapy only changes cholesterol numbers while leaving atherosclerotic plaque untouched.

The GLAGOV trial examined coronary arteries directly using intravascular ultrasound. Patients with coronary artery disease who were already receiving statin therapy were randomized to evolocumab or placebo. After approximately 18 months, the evolocumab group achieved an average LDL cholesterol level of about 37 mg/dL.

Percent atheroma volume decreased by approximately 0.95 percent with evolocumab while increasing slightly in the placebo group. Plaque regression occurred in a greater proportion of patients receiving evolocumab.

A one-percent change in plaque volume may sound modest, particularly beside a 50–60 percent reduction in LDL cholesterol. Atherosclerotic plaque is established tissue within an artery, however, not excess cholesterol floating freely in the bloodstream. Meaningful changes in plaque biology occur more slowly.

Subsequent intracoronary imaging studies have provided additional evidence that intensive LDL lowering with evolocumab can reduce lipid content, increase fibrous-cap thickness and produce changes consistent with greater plaque stability.

That may be just as important as plaque regression. Heart attacks often occur when an atherosclerotic plaque becomes unstable, ruptures or erodes and triggers formation of a blood clot. Cardiovascular prevention is therefore concerned not only with how much plaque exists, but also with reducing the likelihood that plaque produces a clinical event.

Where Repatha Fits When Statins Cause Problems

Statins remain first-line lipid-lowering treatment for many patients because the evidence base is extensive, cardiovascular outcomes are well established and generic medications are inexpensive. That does not mean every patient tolerates them.

Some patients develop genuine statin-associated muscle pain, weakness or other adverse effects. The clinical response should not be to dismiss those symptoms, nor should one episode automatically establish lifelong intolerance to every statin at every dose.

Depending on cardiovascular risk, clinicians may consider a different statin, a lower dose, intermittent dosing, ezetimibe, bempedoic acid, a PCSK9 inhibitor or combinations of these approaches.

Repatha can be particularly useful when the reduction required is large. Ezetimibe typically lowers LDL considerably less than a PCSK9 monoclonal antibody. Bempedoic acid provides another oral option and has cardiovascular-outcome evidence, especially relevant for patients who cannot tolerate statins. Evolocumab generally produces a larger LDL reduction than either drug used alone.

The treatment decision therefore depends less on which medication is considered philosophically preferable and more on how much cardiovascular risk is present, how much LDL and ApoB reduction is needed, which therapies the patient can tolerate and what the patient is willing and able to use consistently.

Familial Hypercholesterolemia Is Different

Familial hypercholesterolemia deserves particular attention because it illustrates why lifestyle and medication should not be treated as competing explanations for high cholesterol.

Someone can exercise regularly, maintain a healthy body composition, eat thoughtfully and still have very high LDL because of inherited differences in LDL-receptor biology and cholesterol clearance.

In heterozygous familial hypercholesterolemia, one altered copy of a gene involved in LDL metabolism can lead to lifelong exposure to elevated LDL. Homozygous familial hypercholesterolemia is much rarer and considerably more severe.

For these patients, addressing nutrition, metabolic health, blood pressure, smoking and physical activity remains important. Those interventions may not lower LDL sufficiently because they do not correct the underlying inherited defect in LDL clearance.

PCSK9 inhibition can therefore have an important role in familial hypercholesterolemia, sometimes in combination with a statin, ezetimibe or other lipid-lowering therapy.

What About Lipoprotein(a)?

Repatha also lowers lipoprotein(a), or Lp(a), but this effect needs to be kept in perspective.

Lp(a) is largely genetically determined and is an independent cardiovascular risk factor. Diet and exercise have relatively little effect on its concentration.

In an analysis of more than 25,000 FOURIER participants, evolocumab reduced Lp(a) by a median of approximately 27 percent at 48 weeks.

That is meaningful, but it is considerably smaller than the LDL reduction achieved with the medication. Repatha should therefore not be presented as an Lp(a)-specific treatment.

For someone with elevated Lp(a), one practical strategy is to treat the cardiovascular risk that can be modified aggressively, including LDL and ApoB burden, blood pressure, metabolic health and smoking exposure. Dedicated Lp(a)-lowering therapies are an active area of pharmaceutical development.

Does Driving LDL Very Low Harm the Brain?

This question deserves attention because cholesterol is biologically important in the nervous system and because concerns about statins and cognition are common among patients.

The brain, however, synthesizes most of its own cholesterol. Peripheral LDL cholesterol does not simply cross into the brain and supply neurons with their cholesterol requirements.

The EBBINGHAUS study was designed specifically to examine cognition in patients participating in FOURIER. Researchers used formal neuropsychological testing rather than relying only on spontaneous reports of memory problems.

They found no significant difference in cognitive performance between patients receiving evolocumab and those receiving placebo. Patient-reported cognitive function was also similar between groups.

This is particularly relevant because many participants achieved LDL levels that would once have been considered unusually low. The trial did not show evidence that those very low LDL concentrations impaired memory, executive function or other measured cognitive domains during the study period.

That does not mean cognition should never be discussed when a patient reports a change. New cognitive symptoms deserve appropriate medical evaluation. It does mean that randomized evidence has not supported the claim that intensive LDL reduction with evolocumab causes cognitive deterioration.

How Repatha Is Taken

Repatha is administered as a subcutaneous injection.

For adults with primary hyperlipidemia or cardiovascular indications, commonly used dosing is 140 mg every two weeks or 420 mg once monthly. The appropriate regimen depends on the indication and should follow the current prescribing information.

For some patients, an injection every two weeks sounds less convenient than taking a tablet each morning. Others prefer an intermittent injection to remembering another daily medication.

Consistency still matters. The cardiovascular benefit of lipid-lowering therapy depends on sustained reduction in atherogenic particle exposure, not an occasional good LDL measurement.

Side Effects and Safety

Repatha is generally well tolerated in clinical trials, but no prescription medication should be described as free of adverse effects.

Injection-site reactions can occur. Other reported adverse effects have included nasopharyngitis, upper respiratory symptoms, influenza and back pain. Hypersensitivity reactions are possible and require appropriate medical attention.

The medication has not produced the same pattern of muscle symptoms associated with statins, which is one reason it may be considered in some patients who cannot tolerate adequate statin therapy.

Long-term treatment decisions should still consider the patient's medical history, other medications, cardiovascular risk, response to therapy and practical ability to continue treatment.

Repatha vs. Ezetimibe vs. Bempedoic Acid

These therapies should not be viewed as contestants competing for a single place in cardiovascular medicine. They work through different pathways and can sometimes be used together.

Ezetimibe is an oral medication that reduces intestinal cholesterol absorption. It is inexpensive as a generic and typically lowers LDL by roughly 15–20 percent when used alone, with additional lowering when added to a statin.

Bempedoic acid is also oral. It inhibits ATP-citrate lyase, an enzyme upstream of HMG-CoA reductase in the cholesterol-synthesis pathway. Current evidence suggests LDL reductions of approximately 20 percent when used alone, with greater reductions when combined with ezetimibe. The CLEAR Outcomes trial demonstrated cardiovascular benefit in a population that included many patients unable or unwilling to take guideline-recommended statin doses.

PCSK9 monoclonal antibodies such as Repatha generally produce a substantially larger LDL reduction, commonly in the 45–60 percent range depending on the clinical setting and accompanying therapy. They also have randomized cardiovascular-outcome evidence.

The trade-off is that Repatha requires injection and is considerably more expensive than generic statins or ezetimibe. Insurance authorization can also be more complicated.

Cost and Insurance Coverage

Cost has historically been one of the biggest barriers to PCSK9 therapy. Prices have come down considerably since these drugs first entered the market, and insurance coverage has expanded, but coverage does not mean every patient receives the medication without restrictions.

Prior authorization is still common. An insurer may request documentation of the patient's LDL level, cardiovascular history, familial hypercholesterolemia, previous treatment with statins or ezetimibe, or evidence that other therapies were not tolerated or did not produce adequate LDL reduction.

Manufacturer assistance or copay programs may reduce out-of-pocket cost for some commercially insured patients, subject to eligibility requirements. Those programs generally do not apply in the same way to Medicare and other government insurance programs.

Coverage policies change, so the useful question for an individual patient is not simply, "Does insurance cover Repatha?" It is whether that patient's plan covers it for that indication and what documentation is required.

The 2026 Dyslipidemia Guideline Gives Clinicians More Flexibility

The 2026 ACC/AHA multisociety guideline on dyslipidemia reflects how much lipid management has changed.

Statins remain foundational treatment for many patients, but contemporary care is no longer limited to escalating the statin dose and waiting. When LDL remains above an appropriate treatment goal, clinicians can select among evidence-based nonstatin therapies including ezetimibe, bempedoic acid and PCSK9 monoclonal antibodies according to cardiovascular risk, the magnitude of LDL reduction required, previous treatment and individual patient characteristics.

The guideline also places more emphasis on ApoB, lipoprotein(a), coronary artery calcium and overall cardiovascular risk rather than treating a single cholesterol number in isolation.

For patients with established atherosclerotic cardiovascular disease at very high risk, the recommended LDL goal is now below 55 mg/dL. Achieving that level may require combination therapy.

Who Might Reasonably Discuss Repatha With Their Physician?

Repatha may be worth discussing when someone has established atherosclerotic cardiovascular disease and remains above an appropriate LDL or ApoB target despite treatment, when a large LDL reduction is required, when familial hypercholesterolemia produces lifelong high LDL exposure, or when adequate statin therapy cannot be tolerated.

An elevated Lp(a) may strengthen the rationale for aggressive reduction of other ApoB-containing particles, although Repatha should not be mistaken for a dedicated Lp(a) treatment.

What matters most is the patient's underlying disease burden. A person with documented coronary plaque, carotid plaque, peripheral arterial disease or a previous cardiovascular event has a very different risk-benefit calculation from someone with a mildly elevated LDL level and little evidence of atherosclerosis.

The Larger Cardiovascular Conversation

Repatha illustrates why the cholesterol debate is often framed too narrowly.

The choice is not between addressing the "root cause" and prescribing medication. Nor is it between lifestyle medicine and conventional medicine.

A patient can have insulin resistance that deserves treatment, hypertension that needs better control, inadequate exercise, poor sleep, a genetically elevated Lp(a), an ApoB burden that remains too high, and coronary plaque that has already developed. Each of those issues can matter at the same time.

Good preventive cardiology identifies the risks that can be modified and addresses them in proportion to their importance.

For some people, excellent lifestyle treatment may be enough. For others, genetics and established atherosclerosis make medication an important addition. Some patients tolerate statins easily. Some do not. Some reach an appropriate ApoB and LDL level with a statin or ezetimibe. Others require combination therapy or a PCSK9 inhibitor.

The objective is not to defend a particular medication. It is to reduce the probability that atherosclerosis eventually becomes a heart attack, stroke, disability or premature death while exposing the patient to no more treatment than the clinical situation justifies.

Related HormoneSynergy® Reading

ApoB and Longevity: The Most Important Cardiovascular Risk Marker You're Probably Not Tracking

Lipoprotein(a) and Longevity: The Genetic Cardiovascular Risk Marker You Cannot See on a Standard Lipid Panel

Statins and Muscle Loss: What the New Study Really Shows

Preventive Cardiology & Longevity Medicine

Coronary Calcium Score vs. CCTA vs. Cleerly® Plaque Analysis

Research & Further Reading

• Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. FOURIER. New England Journal of Medicine.
• Nicholls SJ, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. GLAGOV. JAMA.
• O'Donoghue ML, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation.
• Giugliano RP, et al. Cognitive Function in a Randomized Trial of Evolocumab. EBBINGHAUS. New England Journal of Medicine.
• Nicholls SJ, et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden Following Myocardial Infarction. JACC: Cardiovascular Imaging.
• 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia.
• Repatha® (evolocumab) U.S. Prescribing Information.

Frequently Asked Questions

Is Repatha a statin?

No. Repatha is a monoclonal antibody that inhibits PCSK9. Statins work through a different pathway by inhibiting cholesterol synthesis in the liver.

Can Repatha be used if someone cannot tolerate statins?

It may be considered in some patients who cannot tolerate adequate statin therapy, particularly when cardiovascular risk is high or a large reduction in LDL and ApoB is needed. Insurance requirements vary.

Does Repatha remove plaque?

Coronary imaging studies have demonstrated modest regression of atherosclerotic plaque with evolocumab and changes consistent with greater plaque stability. It does not make established atherosclerosis disappear.

Does Repatha lower lipoprotein(a)?

Yes. Evolocumab lowered Lp(a) by approximately 27 percent in a FOURIER analysis. That reduction is meaningful but substantially smaller than its effect on LDL, and Repatha is not considered an Lp(a)-specific therapy.

Does very low LDL from Repatha cause dementia?

Randomized cognitive testing in the EBBINGHAUS study did not demonstrate worsening cognitive performance with evolocumab compared with placebo, including among patients who achieved very low LDL levels.

How often is Repatha given?

Common adult dosing regimens include 140 mg by subcutaneous injection every two weeks or 420 mg once monthly, depending on the indication and current prescribing guidance.

This article is provided for educational purposes and is not individual medical advice. Lipid-lowering therapy should be selected according to a person's cardiovascular risk, medical history, laboratory findings, medication tolerance, evidence of atherosclerosis and treatment goals in consultation with a qualified clinician.